Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Messina

Showing results (81-90 of 97) with videos related to

Pageof 10
Sort By:
Frontiers in Psychiatry|April 27, 2026
Association between baseline circulating FGF21 levels and depressive symptoms at follow up in older adults: evidence from the FRASNET cohortSarah Damanti, Clara Sciorati, Amanda Avola, et al.
Mechanisms of Ageing and Development|November 13, 2025
Circulating mitokines GDF-15 and FGF21 are associated with frailty, sarcopenia, and malnutrition in older adults: Evidence from the FRASNET studySarah Damanti, Clara Sciorati, Rebecca De Lorenzo, et al.
Immunotherapy|August 19, 2024
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumabAlessandra Damassi, Malvina Cremante, Alessio Signori, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2023
Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the "CARACAS" studyAlessandra A Prete, Paolo Manca, Marco Messina, et al.
Journal for Immunotherapy of Cancer|November 24, 2021
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS studySara Lonardi, Alessandra Anna Prete, Federica Morano, et al.
Clinical Genitourinary Cancer|May 22, 2024
Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25)Elisabetta Gambale, Marco Maruzzo, Carlo Messina, et al.
Cancer Immunology, Immunotherapy : CII|February 14, 2026
Site and number of metastases predict outcomes in avelumab maintenance for advanced UC: results from meet-URO 25Giandomenico Roviello, Elisabetta Gambale, Irene De Gennaro Aquino, et al.
Frontiers in Immunology|June 29, 2026
Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) studyGiandomenico Roviello, Elisabetta Gambale, Irene De Gennaro Aquino, et al.
The Oncologist|November 20, 2025
Real-world effectiveness of Avelumab maintenance in advanced urothelial carcinoma: results from the Italian multicenter MALVA study (Meet-URO 25)Giandomenico Roviello, Elisabetta Gambale, Irene De Gennaro Aquino, et al.
Clinical Genitourinary Cancer|May 1, 2026
Concomitant medications and survival outcomes in patients receiving avelumab maintenance for advanced urothelial carcinoma: sub analysis of Meet-URO 25 studyGiandomenico Roviello, Martina Catalano, Elisabetta Gambale, et al.
Pageof 10

Showing results (81-90 of 97) with videos related to

Sort By:
Pageof 10
Frontiers in Psychiatry|April 27, 2026
Association between baseline circulating FGF21 levels and depressive symptoms at follow up in older adults: evidence from the FRASNET cohortSarah Damanti, Clara Sciorati, Amanda Avola, et al.
Mechanisms of Ageing and Development|November 13, 2025
Circulating mitokines GDF-15 and FGF21 are associated with frailty, sarcopenia, and malnutrition in older adults: Evidence from the FRASNET studySarah Damanti, Clara Sciorati, Rebecca De Lorenzo, et al.
Immunotherapy|August 19, 2024
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumabAlessandra Damassi, Malvina Cremante, Alessio Signori, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2023
Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the "CARACAS" studyAlessandra A Prete, Paolo Manca, Marco Messina, et al.
Journal for Immunotherapy of Cancer|November 24, 2021
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS studySara Lonardi, Alessandra Anna Prete, Federica Morano, et al.
Clinical Genitourinary Cancer|May 22, 2024
Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25)Elisabetta Gambale, Marco Maruzzo, Carlo Messina, et al.
Cancer Immunology, Immunotherapy : CII|February 14, 2026
Site and number of metastases predict outcomes in avelumab maintenance for advanced UC: results from meet-URO 25Giandomenico Roviello, Elisabetta Gambale, Irene De Gennaro Aquino, et al.
Frontiers in Immunology|June 29, 2026
Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) studyGiandomenico Roviello, Elisabetta Gambale, Irene De Gennaro Aquino, et al.
The Oncologist|November 20, 2025
Real-world effectiveness of Avelumab maintenance in advanced urothelial carcinoma: results from the Italian multicenter MALVA study (Meet-URO 25)Giandomenico Roviello, Elisabetta Gambale, Irene De Gennaro Aquino, et al.
Clinical Genitourinary Cancer|May 1, 2026
Concomitant medications and survival outcomes in patients receiving avelumab maintenance for advanced urothelial carcinoma: sub analysis of Meet-URO 25 studyGiandomenico Roviello, Martina Catalano, Elisabetta Gambale, et al.
Pageof 10